Literature DB >> 2150816

In vitro susceptibility of "Campylobacter upsaliensis" to twenty-four antimicrobial agents.

M A Preston1, A E Simor, S L Walmsley, S A Fuller, A J Lastovica, K Sandstedt, J L Penner.   

Abstract

The in vitro susceptibility of 41 strains of "Campylobacter upsaliensis" to 24 antimicrobial agents was determined using a broth microdilution procedure. Most isolates were susceptible to the fluoroquinolones and beta-lactam antibiotics tested, but all strains were resistant to trimethoprim (MBCs greater than or equal to 128 micrograms/ml) and teicoplanin (MBCs greater than or equal to 32 micrograms/ml). These agents may be useful in a selective isolation medium for "Campylobacter upsaliensis".

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150816     DOI: 10.1007/bf01967382

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Human disease associated with "Campylobacter upsaliensis" (catalase-negative or weakly positive Campylobacter species) in the United States.

Authors:  C M Patton; N Shaffer; P Edmonds; T J Barrett; M A Lambert; C Baker; D M Perlman; D J Brenner
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

2.  "Campylobacter upsaliensis" isolated from cats as identified by DNA relatedness and biochemical features.

Authors:  J G Fox; K O Maxwell; N S Taylor; C D Runsick; P Edmonds; D J Brenner
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

3.  Characterization and description of "Campylobacter upsaliensis" isolated from human feces.

Authors:  H Goossens; B Pot; L Vlaes; C Van den Borre; R Van den Abbeele; C Van Naelten; J Levy; H Cogniau; P Marbehant; J Verhoef
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

4.  Antimicrobial susceptibility of Campylobacter jejuni with special reference to resistance patterns of Canadian isolates.

Authors:  M A Karmali; S De Grandis; P C Fleming
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

5.  "Campylobacter upsaliensis" isolated from blood cultures of pediatric patients.

Authors:  A J Lastovica; E Le Roux; J L Penner
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

6.  Isolation and characterization of catalase-negative and catalase-weak strains of Campylobacter species, including "Campylobacter upsaliensis," from humans with gastroenteritis.

Authors:  D E Taylor; K Hiratsuka; L Mueller
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

7.  Evaluation of a blood-free, charcoal-based, selective medium for the isolation of Campylobacter organisms from feces.

Authors:  M A Karmali; A E Simor; M Roscoe; P C Fleming; S S Smith; J Lane
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

8.  Plasmid profiles of clinical isolates of Campylobacter with no or weak catalase activity.

Authors:  A J Lastovica; R E Ambrosio
Journal:  S Afr Med J       Date:  1986-09-13

9.  Is "Campylobacter upsaliensis" an unrecognised cause of human diarrhoea?

Authors:  H Goossens; L Vlaes; M De Boeck; B Pot; K Kersters; J Levy; P De Mol; J P Butzler; P Vandamme
Journal:  Lancet       Date:  1990-03-10       Impact factor: 79.321

10.  Inhibition of Campylobacter coli and Campylobacter jejuni by antibiotics used in selective growth media.

Authors:  L K Ng; M E Stiles; D E Taylor
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

View more
  2 in total

Review 1.  The clinical importance of emerging Campylobacter species.

Authors:  Si Ming Man
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-25       Impact factor: 46.802

2.  Detection and characterisation of canine astrovirus, canine parvovirus and canine papillomavirus in puppies using next generation sequencing.

Authors:  Tarka Raj Bhatta; Anthony Chamings; Jessy Vibin; Soren Alexandersen
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.